Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Britannia Pharmaceuticals Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9613243.6Aexternal-prioritypatent/GB9613243D0/en
Application filed by IndividualfiledCriticalIndividual
Publication of CA2251949A1publicationCriticalpatent/CA2251949A1/en
Application grantedgrantedCritical
Publication of CA2251949CpublicationCriticalpatent/CA2251949C/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The invention relates to the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Lofexidine is used for control of ADHD. Typical doses are from 0.005 to 0.02 mg/kg.
CA002251949A1996-06-251997-06-24Use of lofexidine in the manufacture of a medicament for treating attention deficit hyperactive disorder
Expired - LifetimeCA2251949C
(en)
Sulphonamidic compounds as therapeutic agents for treatment of central nervous system, method of obtaining novel sulphonamidic compounds and drugs containing such compounds
2-OPTICALLY ACTIVE AMINOTETRALINE, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT, ACTIVE IN THE PREVENTION AND TREATMENT OF SEPTIC SHOCK.